Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors.

Archive ouverte

Delahaye, Nicolas F | Rusakiewicz, Sylvie | Martins, Isabelle | Ménard, Cédric | Roux, Stephan | Lyonnet, Luc | Paul, Pascale | Sarabi, Matthieu | Chaput, Nathalie | Semeraro, Michaela | Minard-Colin, Véronique | Poirier-Colame, Vichnou | Chaba, Kariman | Flament, Caroline | Baud, Véronique | Authier, Hélène | Kerdine-Römer, Saadia | Pallardy, Marc | Cremer, Isabelle | Peaudecerf, Laetitia | Rocha, Bénédita | Valteau-Couanet, Dominique | Gutierrez, Javier Celis | Nunès, Jacques A | Commo, Frédéric | Bonvalot, Sylvie | Ibrahim, Nicolas | Terrier, Philippe | Opolon, Paule | Bottino, Cristina | Moretta, Alessandro | Tavernier, Jan | Rihet, Pascal | Coindre, Jean-Michel | Blay, Jean-Yves | Isambert, Nicolas | Emile, Jean-François | Vivier, Eric | Lecesne, Axel | Kroemer, Guido | Zitvogel, Laurence

Edité par CCSD ; Nature Publishing Group -

International audience. The natural killer (NK) cell receptor NKp30 is involved in the recognition of tumor and dendritic cells (DCs). Here we describe the influence of three NKp30 splice variants on the prognosis of gastrointestinal sarcoma (GIST), a malignancy that expresses NKp30 ligands and that is treated with NK-stimulatory KIT tyrosine kinase inhibitors. Healthy individuals and those with GIST show distinct patterns of transcription of functionally different NKp30 isoforms. In a retrospective analysis of 80 individuals with GIST, predominant expression of the immunosuppressive NKp30c isoform (over the immunostimulatory NKp30a and NKp30b isoforms) was associated with reduced survival of subjects, decreased NKp30-dependent tumor necrosis factor-α (TNF-α) and CD107a release, and defective interferon-γ (IFN-γ) and interleukin-12 (IL-12) secretion in the NK-DC cross-talk that could be restored by blocking of IL-10. Preferential NKp30c expression resulted partly from a single-nucleotide polymorphism at position 3790 in the 3' untranslated region of the gene encoding NKp30. The genetically determined NKp30 status predicts the clinical outcomes of individuals with GIST independently from KIT mutation.

Consulter en ligne

Suggestions

Du même auteur

NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients

Archive ouverte | Rusakiewicz, Sylvie | CCSD

International audience. Despite effective targeted therapy acting on KIT and PDGFRA tyrosine kinases, gastrointestinal stromal tumors (GIST) escape treatment by acquiring mutations conveying resistance to imatinib m...

Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients.

Archive ouverte | Ménard, Cédric | CCSD

International audience. Clinical outcomes of gastrointestinal stromal tumor (GIST)-bearing patients treated with imatinib mesylate (IM) are variable. Other than the site of mutation within the c-kit gene, prognostic...

Family-based association of a low producing lymphotoxin-alpha allele with reduced Plasmodium falciparum parasitemia

Archive ouverte | Barbier, Mathieu | CCSD

International audience. no abstract

Chargement des enrichissements...